• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Autonomix secures U.S. patent for cancer-treating tech

Autonomix secures U.S. patent for cancer-treating tech

December 30, 2024 By Danielle Kirsh

Autonomix Medical LogoAutonomix today announced it received a patent from the U.S. Patent and Trademark Office (USPTO) for its catheter-based cancer tumor treating technology.

The patent, titled Systems and Methods for Treating Cancer and/or Augmenting Organ Function, covers the company technology, including systems, methods, and devices for interventionally treating cancerous tumors and cancer-related pain. Autonomix plans to use the technology for pancreatic cancer-related pain.

“As we continue to advance the development of this potentially groundbreaking technology, bolstering our patent protection remains a key priority,” CEO Brad Hauser said in a news release. “Supported by recent positive preclinical results demonstrated to date, we believe the depth and breadth of our proprietary technology provides the opportunity for further evaluation and we intend to explore its potential to reduce cancer progression and metastases.”

Autonomix reported positive results from a preclinical study in mice that demonstrated its targeted nerve ablation technology significantly reduced metastases and tumor mass in pancreatic cancer models. The company said the findings suggest that neural pathways play a critical role in the development of pancreatic cancer.

The company’s ongoing proof-of-concept clinical trial in humans is currently focused on pain reduction through targeted nerve ablation near the pancreas. Additional studies are planned to assess whether the preclinical results can be replicated in clinical applications.

Autonomix also plans to investigate further the potential of its nerve ablation technology to slow tumor growth and metastasis in human pancreatic cancer patients.

The technology uses a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. Once the system identifies the target nerves, Autonomix uses radiofrequency ablation technology to kill the nerves and enable a precision-guided sense, treat, and verify approach to addressing a number of disease categories, from chronic pain management to hypertension and cardiology.

Filed Under: Business/Financial News, Catheters, Oncology Tagged With: Autonomix

More recent news

  • Teleflex wins Breakthrough Device designation for Freesolve resorbable scaffold
  • FDA clears Solventum’s combo wound care platform following Acera acquisition
  • GE HealthCare begins new global partnerships to advance theranostic imaging technology
  • Siemens Healthineers, Nvidia launch radiotherapy AI collaboration
  • J&J, Medtronic present pulsed field ablation data from global real-world use

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy